> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Merck Favorable Keytruda Data in Cervical Cancer
- URL: https://www.fdaweb.com/merck-favorable-keytruda-data-in-cervical-cancer/
- Published: 2021-06-22T12:00:00.000Z
- Updated: 2026-09-14T17:04:19.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149591

Merck has reported favorable data from a study investigating its anti-PD-1 therapy Keytruda (pembrolizumab) in combination with platinum-based chemotherapy (paclitaxel plus cisplatin or paclitaxel plus carboplatin), with or without bevacizumab, for first-line treatment of patients with persistent, recurrent or metastatic cervical cancer.

The company says the study (KEYNOTE-826) met its primary endpoints of overall survival and progression-free survival compared to the same platinum-based chemotherapy regimens with or without bevacizumab alone and regardless of PD-L1 status. Keytruda is the first anti-PD-1/PD-L1 therapy to demonstrate this, it adds. Trial data will be presented at an upcoming medical meeting and will be submitted to FDA and other regulatory authorities.

Additionally, Merck says the study will serve as confirmatory evidence for the current accelerated approval for Keytruda in cervical cancer for second-line treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1.